Compare ARK Next Generation Internet ETF (ARKW) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ARK Next Generation Internet ETF vs Novartis AG — how do they compare? ARK Next Generation Internet ETF trades at $148.16, while Novartis AG trades at $153.82 (market cap $298.18B). The key difference: Novartis AG pays a 3.02% dividend while ARK Next Generation Internet ETF pays none, and Novartis AG is trading nearer its 52-week high, ARK Next Generation Internet ETF nearer its low. Which is the better fit depends on your goals.
| ARKW | NVS | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $182.20 | $168.62 |
52-Week Low | $114.45 | $119.31 |
Market Cap | — | $298.18B |
Enterprise Value | — | $339.50B |
Dividend Yield | — | 3.02% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKW trades at $147.92, up 3.11% today, with bullish technical signals from moving averages and a neutral oscillator stance. The ETF focuses on next-generation internet companies including AI and cloud infrastructure plays. Recent analysis highlights near-term headwinds from elevated capital spending but maintains long-term growth potential in agentic AI and physical AI technologies.
The ETF faces market skepticism around current AI infrastructure investments but offers exposure to innovative technology leaders. Key risks include sector concentration and volatility, while institutional interest remains strong in transformative technology themes driving long-term growth prospects.
Novartis (NVS) trades at $156.33, up 1.37% on the day, with a bullish technical signal and strong support near $156. The company reported Q2 2026 earnings that beat expectations, driven by robust oncology drug sales, and reaffirmed full-year guidance. Revenue for 2025 was $56.67 billion with a net income margin of 22.5%, while valuation ratios like P/E of 23.61 and P/B of 7.15 reflect premium pricing. Recent news highlights institutional buying and CEO confidence in the growth pipeline.
The outlook for NVS is positive, supported by earnings momentum and a diversified drug portfolio, but risks include generic competition for Entresto and pricing pressures. Analyst consensus is mixed with 24% buy ratings, indicating cautious optimism. Investment appeal hinges on execution of new drug launches and offsetting legacy product declines.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ARK Next Generation Internet ETF
ARKW is an actively managed ETF that invests in next-generation internet technologies. It focuses on cloud computing, AI, e-commerce, and blockchain innovation, with key holdings like Tesla, Advanced Micro Devices, and Roku.
Read more on ARKW →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
